I agree, I don't think even NP thought this week's news would result in share price appreciation without financing resolved......heck if human cancer data can't move the needle last week, no pre-clinical results, basket trial IND, CROI abstract, new PR partner, etc. will IMO.

While we all share the frustration of the current share price, the science continues to advance and impress. IMO eventually (when the financial woes are resolved), valuation will have to be assigned to some degree. How much will be immediately realized upon a license deal, will some wait until revenues begin, quarterly statements showing these revenues filed, up-listing occurs, etc. is TBD. Either way, IMO at some point the market will become more rational and assign some valuation to CYDY.....watch out if it assigns any future potential indication valuation.

Most of us here as not flipping for pennies and looking for the longer term reward.....so other than prolonged frustration and unrealized losses the current share price means little to me at the moment.